Best Oncology Companies in Capital Region of Denmark, Denmark
The 41 best Oncology companies in Capital Region of Denmark, Denmark in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Symphogen.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Capital Region of Denmark
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Symphogen Developer of recombinant antibody for treatment of cancers | $671M | 87 mo ago | 103 103 → 219 (+113%) | Martin Olin CEO | Acquired | 581 patents Multispecific immune‑checkpoint antibody therapeutics targeting PD‑1, TIM‑3, and LAG‑3 | — |
| 2 | Bavarian Nordic Developer of therapeutic vaccines against cancer and infectious diseases | $185M | 19 mo ago | 35 | — | Public | 1,103 patents Vaccinia-based viral vectors for cancer immunotherapy and vaccine production | — |
| 3 | IO Biotech Developer of vaccine for the treatment of cancer | $175M | 36 mo ago | 15 15 → 36 (+140%) | Mai-Britt Zocca CEO and Founder | Public | 2 patents Therapeutic cancer vaccines and osteoprotegerin ligand inhibition for bone disease treatment | — |
| 4 | Galecto Biotech Developer of galectin modulators for treating idiopathic pulmonary fibrosis | $160M | 71 mo ago | 29 | Hans Schambye President & CEO | Public | 184 patents Small-molecule galectin-1/galectin inhibitors for therapeutic applications | — |
| 5 | Adcendo Developer of antibody-drug conjugates for the treatment of cancer | $113M | 4 mo ago | 23 | Niels Behrendt Co-Founder | Series C | — | — |
| 6 | Ascendis Pharma Integrated biopharmaceutical company to advance its pipeline of long-acting prodrug therapies | $109M | 141 mo ago | 573 573 → 1,416 (+147%) | Jan Moller Mikkelsen CEO & President | Public | 1,472 patents Long-acting protein/peptide therapeutics via albumin-binding conjugates and prodrug designs | — |
| 7 | Scandion Oncology Developer of drugs that specifically target chemotherapy resistance mechanisms | $35M | 69 mo ago | 3 | Jan Stenvang CSO and Co-founder of Scandion Oncology | Seed | 83 patents Novel anticancer small‑molecule SCO‑101 formulations, stable polymorphs, and exposure‑enhancing combos | — |
| 8 | STipe Therapeutics Developer of therapeutics for the treatment of cancer | $23M | 83 mo ago | 16 | — | Series A | 13 patents STING pathway agonists and delivery systems for cancer immunotherapy | — |
| 9 | EpiTherapeutics Developer of therapies to treat cancer | $23M | 148 mo ago | — | John Milligan CEO & President | Acquired | — | — |
| 10 | Commit Biologics Developer of immunotherapies for the treatment of a variety of cancers | $17M | 19 mo ago | 8 | — | Seed | 4 patents Therapeutic antibodies targeting CD20/CD38 and engineered complement‑engaging protein biologics | — |
| 11 | Azanta Developer of medicines for orphan oncology and medical device for women's health monitoring | $16M | 131 mo ago | 3 | Claus Juan Moller San Pedro Founder & ex-CEO | Acqui-Hired | 19 patents Formulation and manufacturing of dispersible solid oral dosage forms, especially misoprostol tablets. | — |
| 12 | Nanovi Developer molecular imaging solutions for cancer | $15M | 99 mo ago | 14 | Simon Hoffmann Executive Director | Series B | 4 patents Fluorescent fiducial markers and brachygel formulations for image‑guided cancer surgery | — |
| 13 | FluoGuide Developer of surgery targeting drugs for cancer patients | $14M | 50 mo ago | 8 | Andreas Kjaer Founder | Series A | 27 patents Fluorophore‑labeled peptides targeting uPAR for molecular imaging and diagnostic agents | — |
| 14 | Curasight Developer of PET ligands for breast cancer indications | $12M | 71 mo ago | 4 | Carsten Nielsen Co-Founder & Director | Series A | 33 patents uPAR-targeted radiolabeled peptides for PET imaging and radionuclide therapy | — |
| 15 | VAR2 Pharmaceuticals Developer of therapeutics to treat cancer | $10M | 122 mo ago | 7 | Ali Salanti CEO | Series A | 49 patents Chondroitin sulfate‑targeted antibody therapeutics and drug‑antibody conjugates | — |
| 16 | TeesuVac Developer of vacuum assisted biopsy gun for the detection of diseases | $5M | 83 mo ago | 7 | Tomas Gundberg Co-Founder | Seed | — | — |
| 17 | 2cureX Provider of in-vitro tests for precision medicines | $5M | 67 mo ago | 4 | — | Funding Raised | 13 patents Predictive biomarkers for colon cancer therapy response and phenotypic drug screening. | — |
| 18 | MonTa Biosciences Developer of liposomes to deliver immunomodulators for the treatment of cancers | $4M | 91 mo ago | 3 | Thomas Andresen Co-Founder | Series A | 4 patents Nanoparticle-based peptide immunotherapies for enhanced immune stimulation and pre‑medication. | — |
| 19 | RhoVac Developer of vaccines for the treatment of metastatic cancer | $3M | 83 mo ago | 4 | — | Public | — | — |
| 20 | ExpreS2ion Biotechnologies Provider of recombinant protein production using an insect expression platform | $2M | 77 mo ago | 32 | — | Public | 35 patents Engineering recombinant proteins with human-like, xylosylated N‑glycans for vaccine/therapeutic use | — |
| 21 | CytoTrack Provider of solutions for the detection of circulating tumor cells | $2M | 94 mo ago | 3 | — | Series A | — | — |
| 22 | Pokeacell Developer of T cell therapeutic solutions for cancer treatment | $1M | 77 mo ago | 8 | Soren Jakobsen Co-Founder | Seed | — | — |
| 23 | Spiromagic Provider of a smartphone connected spirometer to measure lung function | $704K | 100 mo ago | 3 | Martin Hansen Co-Founder | Seed | — | — |
| 24 | Oncology Venture Developer of drugs for the treatment of cancer | $532K | 74 mo ago | 14 | Peter Buhl Jensen ex-Founder | Public | 31 patents Predictive molecular profiling to forecast cancer drug response and personalize oncology therapy. | — |
| 25 | BioScopeX Developer of tool for diagnosis of some forms of cancer | $207K | 81 mo ago | 1 | Ebbe Nordskov Co-Founder | Seed | — | — |
| 26 | Ankrin Therapeutics Developer of structure-based drugs for cancer | $169K | 71 mo ago | 2 | Anja Groth Co-Founder | Seed | — | — |
Top 12 Oncology companies in Capital Region of Denmark
#1
Series C · Frederiksberg, Capital Region of Denmark · founded 2017 · 23 employees$113Mraised▾
Developer of antibody-drug conjugates for the treatment of cancer. The company's drug is developed to target specialized endocytic receptors that are uPARAP and endo180. It allows targeted therapy in cancer, including soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.
- Apr 2026Series C$75M
- Nov 2024Series B$135M
- May 2024Series A$17.4M
- Apr 2023Series A$33.9M
#2
Public · Hellerup, Capital Region of Denmark · founded 1994 · 35 employees$185Mraised▾
Developer of therapeutic vaccines against cancer and infectious diseases. The company has proprietary poxviral-based vaccine platform technologies, to develop medicines that address a wide variety of infectious diseases and cancers. The company has developed a pipeline for Smallpox, RSV, COVID-19 and Immuno-oncology.
- Jan 2025Grant (prize money)$1.5M
- Mar 2021Post IPO$183.4M
#3
Seed · Aarhus, Capital Region of Denmark · founded 2021 · 8 employees$17.2Mraised▾
Developer of immunotherapies for the treatment of a variety of cancers. The company combines expertise in antibody development and complement research to refine the BiCE technology and creates a new type of immunotherapy for the treatment of a variety of cancers.
- Jan 2025Seed$5.8M
- May 2024Seed$17.2M
#4
Public · Copenhagen, Capital Region of Denmark · founded 2014 · 15 employees$175.3Mraised▾
IO Biotech is a developer of vaccine-based cancer treatments. Its technology is based on inducing or activating anti Tregs which kill the immunosuppressive and remove the immune suppression allowing for intratumoral inflammation and subsequent elimination of cancer cells. Its lead candidate IO-101, a peptide vaccine is currently in phase 2 trials for melanoma and is in phase 1 for Non-small cell lung cancer (NSCLC). The company is also conducting research on PD-L1 (programmed death-ligand 1) which may serve as a target for immunotherapeutic strategies.
- Aug 2023Post IPO—
- Jan 2021Series B$154.5M
- Dec 2016Series A$8.9M
- Jan 2016Series A$12M
#5
Acquired · Ballerup, Capital Region of Denmark · founded 2000 · 103 employees$671.5Mraised▾
Symphogen has developed recombinant polyclonal antibodies (rpAb) for the treatment of cancer. The company creates optimally selected antibody mixtures to target multiple oncology targets in a single drug product. The lead oncology product, Sym004, is being investigated in two new clinical studies – one in patients with metastatic colorectal cancer and others in patients with Non-Small Cell Lung Cancer. Sym004 completed is phase 2 of clinical study and is an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR). Other products are Sym 015 in phase 1 of the clinical trial for lung cancer among others.
- May 2019Series F$58.8M
- Nov 2017Series F$5M
- Oct 2015Series F$76.6M
- May 2013Series F$185.8M
#6
Public · Copenhagen, Capital Region of Denmark · founded 2010 · 29 employees$160.5Mraised▾
Galecto Biotech is a clinical-stage biopharma developing galectin modulators for idiopathic pulmonary fibrosis and other severe diseases, including fibrosis and cancer. It has developed ultra-potent galectin-3 inhibitors that specifically block the binding of galectin-3 to carbohydrate structures. The lead candidate, TD-139, completed Phase Ib/IIa trials. TD139 is a highly potent, specific inhibitor of the galactoside binding pocket of galectin-3. TD139 was initially developed by a team.
- Sep 2020Series D$64.2M
- Oct 2018Series C$90M
- Oct 2013Series A$6.3M
- May 2012Seed—
#7
Seed · Copenhagen, Capital Region of Denmark · founded 2016 · 3 employees$35.5Mraised▾
Scandion Oncology is developing a pipeline of therapies for the treatment of chemotherapy resistance. Their lead candidate SCO-101, has completed Phase I trials and is about to start Phase 2 for metastatic breast cancer and metastatic colorectal cancer. Other candidates include SCO-201 for solid tumors (late preclinical).
- Nov 2020Seed$27.2M
- Sep 2019Grant (prize money)$54.7K
- Jul 2019Seed$5M
- Apr 2019Grant (prize money)$52.6K
#8
Public · Hellerup, Capital Region of Denmark · founded 2007 · 573 employees$108.7Mraised▾
Ascendis Pharma develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil for the treatment of pulmonary arterial hypertension. Also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection for the treatment of Age-related Macular Edema (AMD). It has strategic collaborations with Sanofi and Genentech.
#9
Series A · Copenhagen, Capital Region of Denmark · founded 2018 · 8 employees$13.9Mraised▾
Developer of surgery targeting drugs for cancer patients. The lead product FG001 contains a fluorophore that is injected into the patient’s vein prior to surgery binds to cancer cells expressing a marker of cancer uPAR and lights up cancer cells and their invasive growth into the surrounding tissue.
- Jun 2022Grant (prize money)$52.4K
- May 2021Series A$9M
- Jul 2020Grant (prize money)$2.8M
- Feb 2020Seed$2.6M
#10
Series A · Aarhus, Capital Region of Denmark · founded 2018 · 16 employees$23.4Mraised▾
Developer of therapeutics for the treatment of cancer. The company has developed drugs that target intracellular protein-protein interactions of the STING pathway that increase the sensitivity of the innate immune system to detect tumour-DNA, enabling patients to prevent the further growth of tumor cells.
- Sep 2019Series A$23.4M
#11
Series A · Copenhagen, Capital Region of Denmark · founded 2013 · 4 employees$11.5Mraised▾
Developer of PET ligands for breast cancer indications. It provides PET imaging target based on the urokinase-type plasminogen activator receptor (uPAR) for breast cancer diagnose. They are focused on developing disease-specific PET ligands for multiple cancer indications.
- Sep 2020Series A$7.4M
- Jun 2017Seed$2.2M
- Jun 2015Seed$1.3M
- May 2014Seed$603.5K
#12
Acquired · Copenhagen, Capital Region of Denmark · founded 2008$23Mraised▾
Developer of therapies to treat cancer. The company is focusing on the development of small-molecule inhibitors against selected epigenetic oncology targets. The company has developed products that target histone demethylases and methyltransferases.
- Apr 2014Series A$14.6M
- Feb 2013Series A$6.5M
- Dec 2010Seed—
- Aug 2010Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in Denmark
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 210 Denmark-affiliated papers.
- University of Copenhagen64
- Aarhus University45
- Copenhagen University Hospital41
- Technical University of Denmark26
- Aarhus University Hospital26
- Tumor microenvironment30
- Immune system25
- Cancer research22
- Immunotherapy21
- Cancer immunotherapy15
- Tumor microenvironment2→32
- Immunotherapy1→27
- Cancer research2→21
- Cancer immunotherapy2→18
- Immunology1→7
- Immunotherapy2→14
- Immune system1→11
- Cancer immunotherapy1→8
- Cancer research1→4
Where oncology is researched across Denmark
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.